On the other hand, promising tumor activity was seen with BYL719, a PI3K class I α isoform inhibitor, when combined with cetuximab in a phase Ib study [38] suggesting that efficacy of isoform specific PI3K inhibitors may be different from that of pan-PI3K inhibitors in HNSCC. Here, PIK3CA is linked to head and neck squamous cell carcinoma.